• Wildcard: BICO, Bioprinting, and Bioconvergence

  • Dec 15 2021
  • Length: 26 mins
  • Podcast

Wildcard: BICO, Bioprinting, and Bioconvergence

Listen for free

View show details

  • Summary

  • We get back to Wednesday's healthcare roots with a rundown on BICO Group, a Sweden-based business that enables researchers and scientists to model, build, test, analyze and observe 3-D printed cells, tissues and organs.

    This company helps researchers reduce the time and cost of identifying potentially efficacious drugs and can help provide initial results on whether drug compounds are safe and effective before having to test them on animals or humans.

    We talk through the huge implications it could have for research in life sciences and personalized medicine and try to clear up some of the jargon around the company.

    Stocks: (OM:BICO)

    Check out more of our content here:

    Podcasts

    Youtube

    Twitter

    Reach us by Email @ IndustryFocus@fool.com
    Show more Show less
Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about Wildcard: BICO, Bioprinting, and Bioconvergence

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available